{{ variable.name }} : {{ variable.values[selectedVariantsIndex[variable_index]].name }}
Quantity:
ARA-290 (also known as cibinetide) is an experimental 11-amino-acid synthetic peptide derived from the helix-B region of erythropoietin (EPO).
Key Characteristics & Mechanism
• Target Receptor: It selectively activates the Innate Repair Receptor (IRR).
• No Red Blood Cell Stimulation: Unlike native EPO, ARA-290 promotes anti-inflammatory and tissue-protective pathways without increasing hematocrit or causing blood-thickening side effects.
• Nerve Regeneration: Preclinical and early-phase clinical studies have focused on its potential to reduce neuropathic pain and support small nerve fiber density in conditions like small fiber neuropathy (SFN), sarcoidosis, and type 2 diabetes.
• Clinical Trials: While early Phase 2 trials showed promise for symptom reduction in diabetic and sarcoidosis-associated neuropathy, larger phase 3 trials have not been completed.